FDA greenlights first all-oral, fixed-duration combo therapy for untreated CLL patients

The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy

FDA accepts Roche’s new drug application for Giredestrant in advanced breast cancer

The NDA filing is supported by results from the phase III evERA Breast Cancer study

BIOEMTECH & NorthStar strike deal to boost access to critical Actinium-225 for preclinical research

The agreement ensures BIOEMTECH customers can consistently obtain Ac-225 for preclinical studies

Asahi Kasei Pharma & Alchemedicine launch first human trials for hard-to-treat diseases drugs

Zydus receives final approval from USFDA for Bosentan tablets for oral suspension, 32 mg

Bosentan 32 mg tablets for oral suspension are indicated for the treatment of Pulmonary Arterial Hypertension

GSK’s Exdensur wins EU nod for severe asthma

The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen

Pfizer’s BRAFTOVI regimen shows major breakthrough in aggressive colorectal cancer

BREAKWATER is a Phase 3, randomized, open-label trial testing BRAFTOVI in combination with cetuximab, either alone or with chemotherapy, in patients with untreated BRAF V600E-mutant mCRC

Evogene and QUT join forces to tackle chemotherapy-resistant lung cancer with AI

Dr Adams’ lab recently uncovered a novel cellular detoxification pathway driving Cisplatin resistance in NSCLC

QCIL to build 350+ bed state-of-the-art CARE Hospital in Nagpur

Sanofi Healthcare expands Hyderabad Global Hub, boosts capacity to 4,500 staff

Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem